J Dent Anesth Pain Med.  2016 Mar;16(1):67-71. 10.17245/jdapm.2016.16.1.67.

Deep sedation for dental treatment in a Down syndrome patient with Eisenmenger syndrome: A case report

Affiliations
  • 1Department of Dental Anesthesiology, School of Dentistry, Seoul National University, Seoul, Korea. stone90@snu.ac.kr

Abstract

Eisenmenger syndrome (ES) is characterized by pulmonary arterial hypertension and right-to-left shunting. The signs and symptoms of ES include cyanosis, shortness of breath, fatigue, hemoptysis, and sudden death. In patients with ES, it is important that the systemic and pulmonary circulations be properly distributed and maintained. General dental treatment is not known to be particularly dangerous. To control pain and anxiety, local anesthetics without epinephrine are usually recommended. However, in cases of difficulty of cooperation, general anesthesia for dental treatment makes the condition worse. In the present case, intravenous deep sedation with propofol and remifentanil was administered for behavioral management during dental treatment successfully.

Keyword

Deep sedation; Dental treatment; Down syndrome; Eisenmenger syndrome; Propofol; Remifentanil

MeSH Terms

Anesthesia, General
Anesthetics, Local
Anxiety
Cyanosis
Death, Sudden
Deep Sedation*
Down Syndrome*
Dyspnea
Eisenmenger Complex*
Epinephrine
Fatigue
Hemoptysis
Humans
Hypertension
Propofol
Anesthetics, Local
Epinephrine
Propofol

Figure

  • Fig. 1 After cardiac catheterization, a right-to-left shunt and severe pulmonary hypertension are observed. (Yellow numbers indicate oxygen saturation and black numbers indicate blood pressure).

  • Fig. 2 Capnography was measured while oxygen was being supplied through a nasal cannula. A mouth gag is used to access the mouth under deep sedation, and a rubber dam is used to prevent water from entering the oral cavity.

  • Fig. 3 Changes in the target concentrations of perioperative propofol and remifentanil and patient vital signs.


Reference

1. Hopkins WE. Severe pulmonary hypertension in congenital heart disease: A review of eisenmenger syndrome. Curr Opin Cardiol. 1995; 10:517–523.
2. Raines DE, Liberthson RR, Murray JR. Anesthetic management and outcome following noncardiac surgery in nonparturients with eisenmenger's physiology. J Clin Anesth. 1996; 8:341–347.
Article
3. Kunimatsu T, Greenan S, Yamashita A, Yamamoto T, Ikeda M. Use of moderate sedation for a patient with down syndrome, intellectual disability, and eisenmenger syndrome: A case report. Spec Care Dentist. 2011; 31:41–43.
Article
4. Pastore E, Marino B, Calzolari A, Digilio MC, Giannotti A, Turchetta A. Clinical and cardiorespiratory assessment in children with down syndrome without congenital heart disease. Arch Pediatr Adolesc Med. 2000; 154:408–410.
Article
5. Oechslin E, Mebus S, Schulze-Neick I, Niwa K, Trindade PT, Eicken A, et al. The adult patient with eisenmenger syndrome: A medical update after dana point part iii: Specific management and surgical aspects. Curr Cardiol Rev. 2010; 6:363–372.
Article
6. Somerville J. How to manage the eisenmenger syndrome. Int J Cardiol. 1998; 63:1–8.
Article
7. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998; 19:1845–1855.
Article
8. Bennett JM, Ehrenfeld JM, Markham L, Eagle SS. Anesthetic management and outcomes for patients with pulmonary hypertension and intracardiac shunts and eisenmenger syndrome: A review of institutional experience. J Clin Anesth. 2014; 26:286–293.
Article
9. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and eisenmenger's syndrome. Drugs. 2008; 68:1049–1066.
Article
10. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Guidelines from the american heart association: A guideline from the american heart association rheumatic fever, endocarditis and kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. J Am Dent Assoc. 2007; 138:739–745. 747–760.
11. Lumley J, Whitwam JG, Morgan M. General anesthesia in the presence of eisenmenger's syndrome. Anesth Analg. 1977; 56:543–547.
Article
12. Manley MC, Skelly AM, Hamilton AG. Dental treatment for people with challenging behaviour: General anaesthesia or sedation? Br Dent J. 2000; 188:358–360.
Article
13. Schwilden H, Schuttler J. Target controlled anaesthetic drug dosing. Handb Exp Pharmacol. 2008; 425–450.
Article
14. Lee BS, Shin TJ, Kim HJ, Choi YJ, Lee SE, Chang JH, et al. Effect site concentrations of propofol for dental treatment under deep sedation in intellectually disabled patients. J Korean Dent Soc Anesthesiol. 2014; 14:167–172.
Article
15. Kiyama S, Yoshikawa T. Target-controlled infusion of propofol for the difficult airway. Anaesth Intensive Care. 1998; 26:591–592.
16. Sung J, Kim HJ, Choi YJ, Lee SE, Seo KS. Comparison of efficacy of propofol when used with or without remifentanil during conscious sedation with a target-controlled infuser for impacted teeth extraction. J Korean Dent Soc Anesthesiol. 2014; 14:213–219.
Article
Full Text Links
  • JDAPM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr